NEW YORK, July 15 (GenomeWeb News) - Europroteome, based in Berlin-Hennigsdorf, Germany, announced Thursday that it has extended a research collaboration with Abbott Laboratories for the discovery and development of novel breast cancer diagnostic tests.
The firms extended the collaboration after reaching a project milestone. The extension triggers a milestone payment from Abbott to Europroteome.
Under the initial agreement, which was reached in February 2004, Europroteome is applying its proteomic and bioinformatic technologies to analyze serum samples from women with breast cancer. The collected data are matched with a panel of cancer markers provided by Abbott on Abbott's automated immunoassay platforms.
Abbott Park, Ill.-based Abbott made an upfront payment to Europroteome and has an option for a royalty-bearing license to the results from the collaboration. As part of the pact, Abbott will be responsible for commercial assay development and worldwide sales and marketing.